SAN CARLOS, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company advancing next generation, potentially curative cell therapies for ...
The FIRCE-1 trial for firi-cel in LBCL patients was discontinued due to insufficient therapeutic advantage and safety concerns. Firi-cel showed a 77% overall response rate, but only 18% of complete ...
SAN CARLOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell ...
Cargo Therapeutics, a developer of cell therapies intended to overcome cancer mechanisms that lead to relapse, is stopping its lead program after a safety complication emerged in a clinical trial that ...
The Fund is an actively managed exchange-traded fund (ETF) that seeks current income. In particular, the Fund seeks a 4 percent target annual income level (the Annual 4 percent Target). This target ...
In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...
As of October 30, 2025, Tidal Trust III- FIRE Funds Income Target ETF has gone out of business. Tidal Trust III - FIRE Funds Income Target ETF is an exchange traded fund launched and managed by Tidal ...
CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a competitive benefit-risk profile for patients. CARGO to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results